UK approves Pharming's Joenja for children aged 4-11 with APDS weighing at least 27 kg

By Public Technologies11:13 (UTC), 6 November 2026 Updated

The U.K. MHRA expanded Pharming's Joenja (leniolisib) authorization, making it the country's first treatment specifically approved for children with APDS.
Eligible children must be aged 4 to 11 and weigh at least 27 kg; authorized dosing is 40 mg or 50 mg twice daily.
The expanded indication extends access beyond previously eligible adults and adolescents aged 12 or older.
Joenja is expected to become available to newly eligible patients in February 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001828316-26-000051), on November 06, 2026, and is solely responsible for the information contained therein.